Completed PHASE2 INTERVENTIONAL 1-arm NCT01431196

Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer

Phase II Trial With Autologous Dendritic Cell Vaccination in Patients With Stage II-III HER2 Negative Breast Cancer

Sponsor: Clinica Universidad de Navarra, Universidad de Navarra

Conditions Stage II Breast Cancer Stage III Breast Cancer

Interventions Autologous dendritic cell vaccination

Updated 6 times since 2017 Last updated: May 18, 2016 Started: Feb 28, 2011 Primary completion: Jun 30, 2012 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Stage II Breast Cancer and Stage III Breast Cancer, this trial is completed. The trial is conducted by Clinica Universidad de Navarra, Universidad de Navarra and has accumulated 6 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clinica Universidad de Navarra, Universidad de Navarra
National Institutes of Health (NIH)
Spanish Clinical Research Network - SCReN

Data source: Clinica Universidad de Navarra, Universidad de Navarra

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pamplona, Spain